Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006449
Abstract: Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who… read more here.
Keywords: waldenstr macroglobulinemia; treatment; rate; zanubrutinib treatment ... See more keywords